Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-069237
Filing Date
2025-05-12
Accepted
2025-05-12 16:15:25
Documents
81
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rgnx-20250331.htm   iXBRL 10-Q 2403239
2 EX-10.1 rgnx-ex10_1.htm EX-10.1 1122719
3 EX-31.1 rgnx-ex31_1.htm EX-31.1 13312
4 EX-31.2 rgnx-ex31_2.htm EX-31.2 13312
5 EX-32.1 rgnx-ex32_1.htm EX-32.1 13064
  Complete submission text file 0000950170-25-069237.txt   12781680

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rgnx-20250331.xsd EX-101.SCH 1608163
84 EXTRACTED XBRL INSTANCE DOCUMENT rgnx-20250331_htm.xml XML 2458871
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37553 | Film No.: 25935049
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)